BCL2 and diffuse large B-cell lymphoma: In diffuse large B-cell lymphoma (DLBCL), overexpression of the anti-apoptotic protein BCL-2 is correlated with adverse survival in patients treated with standard rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone (R-CHOP) [4].